Peptides for Addiction Recovery: Selank, BPC-157, and the Opioid System

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

Addiction involves neurobiological changes in dopamine, opioid, and GABA systems. Selank modulates the GABAergic and opioid systems, reducing anxiety and craving. BPC-157 may repair dopamine system damage caused by substance use. Low-dose naltrexone (LDN) modulates the opioid system to reduce cravings.

The Neurobiology of Addiction

Addiction is fundamentally a neurobiological disorder characterized by dysregulation of the brain's reward, motivation, and stress systems. Chronic substance use produces lasting changes in dopamine signaling (reduced reward sensitivity), glutamate signaling (increased craving and compulsive behavior), GABA signaling (increased anxiety and stress sensitivity), and the opioid system (altered pain and pleasure processing). Effective addiction treatment must address these neurobiological changes, not merely manage withdrawal symptoms.

Selank: GABAergic and Opioid Modulation

Selank modulates the GABAergic system — the primary inhibitory neurotransmitter system that is dysregulated in alcohol and benzodiazepine addiction — without producing dependence or tolerance. This makes it potentially valuable for managing the anxiety and stress sensitivity that drives relapse in early recovery. Selank also influences enkephalin metabolism, with potential relevance for opioid addiction recovery. Typical dosing: 250–500 mcg intranasally, 2–3 times daily during the acute recovery phase.

BPC-157 and Dopamine System Repair

Chronic substance use damages the dopamine system — reducing dopamine receptor density and impairing dopamine signaling. This "dopamine deficit" is responsible for the anhedonia (inability to experience pleasure) and motivational deficits that characterize early recovery and drive relapse. BPC-157 has demonstrated the ability to modulate dopamine system function in animal models, potentially supporting the repair of substance-induced dopamine system damage.

Low-Dose Naltrexone (LDN)

LDN (1.5–4.5 mg nightly) modulates the opioid system through a mechanism distinct from standard naltrexone (50 mg daily). By transiently blocking opioid receptors, LDN triggers a compensatory upregulation of endogenous opioid production, which has downstream effects on immune function, inflammation, and reward system regulation. LDN has shown promise for alcohol use disorder, opioid use disorder (in combination with other treatments), and the mood disorders that commonly co-occur with addiction.

Practical Considerations

Peptide-based addiction support should be viewed as a complement to, not a replacement for, evidence-based addiction treatment (medication-assisted treatment, behavioral therapy, peer support). These interventions address the neurobiological substrate of addiction but must be combined with comprehensive addiction medicine care for optimal outcomes.